Dose-response effects of bleomycin on inflammation and pulmonary fibrosis in mice

Toxicological Research

Volumn 26, Issue 3, 2013, Pages 217-222

  Kim, Soo Nam ^a   Lee, Jinsoo ^a,b   Yang, Hyo Seon ^a   Cho, Jae Woo ^c   Kwon, Soonjin ^a,b   Kim, Young Beom ^c   Her, Jeong Doo ^a   Cho, Kyu Hyuk ^a   Song, Chang Woo ^a   Lee, Kyuhong ^a  

^a Korea Institute of Toxicology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Korea Institute of Toxicology   (South Korea)

Author keywords

Bleomycin; Inflammation; Mouse model; Pulmonary fibrosis

Indexed keywords

EID: 84880590323     PISSN: 19768257     EISSN: 22342753     Source Type: Journal    
DOI: 10.5487/TR.2010.26.3.217     Document Type: Article

References (20)

1. Antje, M., Juan Carlos, R.L., Lingqiao, W., Jack, G. and Martin, K. (2006). Models of pulmonary fibrosis. J. Ddmod., 3, 243-249.
2. Bethany, B.M. and Cory, M.H. (2008). Murine models of pulmonary fibrosis. Am J Physiol. Lung Cell Mol Physiol., 294, 152-160.
3. Bonniaud, P., Kolb, M., Galt, T., Robertson, J., Robbins, C., Stampfli, M., Lavery, C., Margetts, P.J., Roberts, A.B. and Gauldie, J. (2004). Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J. Immunol., 173, 2099-2108.
4. Briggs, A.D., Chandler, D.B., Jackson, R.M. and Fulmer, J.D. (1985). The effect of endotoxin on bleomycin-induced lung fibrosis in the rat. Toxicol Lett., 27, 91-96.
5. Brown, R.F., Drawbaugh, R.B. and Marrs, T.C. (1988). An investigation of possible models for the production of progressive pulmonary fibrosis in the rat. The effects of repeated intratracheal instillation of bleomycin. Toxicol., 51, 101-110.
6. Hemmati, A.A., Nazari, Z., Motlagh, M.E. and Goldasteh, S. (2002). The role of sodium cromolyn in treatment of paraquatinduced pulmonary fibrosis in rat. Pharmacol. Res., 46, 229-234.
7. Higashiyama, H., Yoshimoto, D., Kaise, T., Matsubara, S., Fujiwara, M., Kikkawa, H., Asano, S. and Kinoshita, M. (2007). Inhibition of activin receptor-like kinase 5 attenuates Bleomy-cin-induced pulmonary fibrosis. Exp Mol Pathol., 83, 39-46.
8. Jack, G., Martin, K., Kjetil, A., Gail, M., Philippe, B. and David, W. (2006). Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc Am Thorac. Soc., 3, 696-702.
9. John, S.L., et al. (1990). BLEOMYCIN: A pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmac. Ther., 47, 347-358.
10. Manoury, B., Nenan, S., Guenon, I., Lagente, V. and Boichot, E. (2007) Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. Int Immunopharmacol., 7, 900-911.
11. Moeller, A., Ask, K., Warburton, D., Gauldie, J. and Kolb, M. (2008). The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J. Biochem Cell Biol., 40, 362-382.
12. Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M. and Arimura, A. (2008). Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J. Pharmacol., 590, 400-408.
13. Ou, X.-M., Li, W.-C., Liu, D.-S., Li, Y.-P., Wen, F.-Q., Feng, Y.-L., Zhang, S.-F., Huang, X.-Y., Wang, T., Wang, K., Wang, X. and Chen, L. (2009). VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int. Immunopharmacol., 9, 70-79.
14. Ouchi, H., Fujita, M., Ikegame, S., Ye, Q., Inoshima, I., Harada, E., Kuwano, K. and Nakanishi, Y. (2008). The role of collagenases in experimental pulmonary fibrosis. Pulm Pharmacol. Ther., 21, 401-408.
15. Saito, F., Tasaka, S., Inoue, K., Miyamoto, K., Nakano, Y., Ogawa, Y., Yamada, W., Shiraishi, Y., Hasegawa, N., Fujishima, S., Takano, H. and Ishizaka, A. (2008). Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am. J. Respir. Cell. Mol. Biol., 38, 566-571.
16. Steven, E.M., Robin, J.M., Geoffrey, J.L. and Darryl, A.K. (2004). Evaluation of experimental models of idiopathic pulmonary fibrosis. J. Ddmod., 1, 329-336.
17. Thomas, A.W. (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest., 117, 524-529.
18. Thomas, W.H., Joan, E.G., Karen, M.R., Andrew, C.J., Carroll, E.C. and Jerold, A.L. (1981). Bleomycin-induced pulmonary fibrosis: correlation of biochemical, physiological, and histological changes. Toxicol. Appl. Pharmacol., 60, 360-367.
19. Tom, W.-M. and Montgomery, M.R. (1980). Biochemical and morphological assessments of bleomycin pulmonary toxicity in rats. Toxicol. Appl. Pharmacol., 53, 64-74.
20. Zhou, X.-M., Zhang, G.-C., Li, J.-X. and Hou, J. (2007). Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats. J. Ethnopharmacol., 111, 255-264.